Antibiotics

NeoVanc: New study finds no clear benefit from a shorter optimised vancomycin treatment in babies with Gram positive late onset sepsis

2021

NeoVanc, a European trial featured in The Lancet Child & Adolescent Health, has published the findings of the largest neonatal vancomycin efficacy trial ever conducted. NeoVanc was a European, multicentre research study coordinated by Penta and funded by the European Commission’s 7th Framework Programme. It compared the efficacy, safety and pharmacokinetics of an optimised dosing regimen with a standard dosing regimen of vancomycin in infants with late onset sepsis.

Read More

🇬🇧 NeoVanc: New study finds no clear benefit from a shorter optimised vancomycin treatment in babies with Gram positive late onset sepsis

2021

Padova – Italy, November  27th 2021

NeoVanc, a European trial featured in The Lancet Child & Adolescent Health, has published the findings of the largest neonatal vancomycin efficacy trial ever conducted:

  • No clear benefit was seen with the use of an optimised short (5±1 day) course of vancomycin, including a loading dose, compared to a longer (10±2 day) standard course in babies treated for sepsis occurring in hospital,
Read More

Public consultation on the draft WHO Essential Medicines List Antibiotic Book

2021

WHO has launched a public call for comments on the draft of WHO Essential Medicines List Antibiotic Book.

The book provides guidance on the prescribing and use of the antibiotics on the WHO Model List of Essential Medicines for over 30 common infections in both the community and hospital setting for children and adults. The draft publication has been developed by an international expert working group of specialists in infectious diseases,

Read More

NeoVanc trial in the final stretch towards completion!

2020

The second trial in neonatal sepsis sponsored by Penta is now in its final stretch towards completion. This trial is part of the NeoVanc project, which aimed to analyze the adaptability of an off-label medicine, vancomycin, to the specific needs of neonates and infants, by developing an optimal dosing regimen. Coordinated by Penta and funded by the European Commission’s 7th Framework Programme, NeoVanc has successfully recruited almost 250 participants, and involved more than 20 sites in 5 European countries.

Read More

New paper published in WHO Bulletin

2020

There is an urgent global need for more child-friendly antibiotic formulations. Our collaborator Prof. Mike Sharland, together with GARDP and St. George’s, University of London researchers have just published a new paper in the WHO Bulletin investigating international antibiotic sales data of child-appropriate oral formulations of antibiotics, with a focus on dispersible tablets. Globally most child-appropriate oral antibiotics were not sold as dispersible tablets,

Read More

An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial

2020

Authors: Hill LF, Turner MA, Lutsar I, et al; NeoVanc Consortium.

Published in: Trials. 2020;21(1):329

Background Vancomycin has been used in clinical practice for over 50 years; however, validated, pharmacokinetic (PK) data relating clinical outcomes to different dosing regimens in neonates are lacking. Coagulase negative staphylococci (CoNS) are the most commonly isolated organisms in neonatal,

Read More

Implementation and impact of pediatric antimicrobial stewardship programs: a systematic scoping review

2020

Authors: DonĂ  D, Barbieri E, Daverio M, Lundin R, Giaquinto C, Zaoutis T, Sharland M

Published in: Antimicrob Resist Infect Control.2020;9:3

Background Antibiotics are the most common medicines prescribed to children in hospitals and the community, with a high proportion of potentially inappropriate use. Antibiotic misuse increases the risk of toxicity, raises healthcare costs, and selection of resistance.

Read More

Standardising neonatal and pediatric anitibiotic clinical trial design and conduct: the PENTA-ID network review

2019

Authors: Folgori L, Lutsar I, Standing JF, et al.

Published in: BMJ Open. 2019; 9:e032592

Abstract: Antimicrobial development for children remains challenging due to multiple barriers to conducting randomised clinical trials (CTs). There is currently considerable heterogeneity in the design and conduct of paediatric antibiotic studies, hampering comparison and meta-analytic approaches.
Read More

European Antibiotic Awareness Day

2019

Today, 18th of November, is European Antibiotic Awareness Day (EADD), that marks the start of the World Antibiotic Awareness Week (WAAW). WAAW aims to increase global awareness of antibiotic resistance, as well as  encourage best practices among the general public, health workers and policy makers to stop the spread of antibiotic resistance. The latest data from the European Centre for Disease Prevention and Control highlights that across the European Union,

Read More

Article – “R&D for children’s antibiotics: a wake-up call” published in AMR Control

2019

We are delighted to see an article on children’s antibiotics, co-authored by GARDP R&D Director, Dr Seamus O’Brien, Penta’s Chief Scientific Officer, Prof. Theo Zakoutlis and Prof. Mike Sharland, from St. George’s, University of London, published in AMR Control, as governments have been discussing AMR at the World Health Assembly.

In R&D for children’s antibiotics: a wake-up call the authors explain how AMR has a disproportionate effect on children,

Read More

Infection Prevention in Paediatrics: ‘Hand in Hand’ – working together for children

2019

On Tuesday 24th September, the Infection Prevention Disease Society event IP2019 in Liverpool will host the one-day conference: Infection Prevention in Paediatrics: ‘Hand in Hand’- working together for children.

This important event will address paediatric care across areas such as Infection Prevention & Control, Tissue Viability & Wound Care, IV and Infectious Diseases. The programme has been tailored towards all paediatric healthcare workers including: IV Specialist Nurses,

Read More

NeoVanc: pivotal achievement of 200 participants enrolled in the study

2019

We are pleased to celebrate the milestone achievement of the randomisation of 200 participants in the NeoVanc project. Congratulations to all the NeoVanc team!

A special mention needs to be made on the great effort of investigators, co-investigators and all researchers at recruiting sites involved in this key study on the use of Vancomycin in paediatrics. We look forward to continuing our work together towards reaching the project target of 300 evaluable participants and we wish the NeoVanc team the best of luck!

Read More

NeoVanc 3rd Investigators meeting

2017

Read More